Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $18.65

Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) shares gapped up prior to trading on Tuesday . The stock had previously closed at $18.65, but opened at $19.86. Calliditas Therapeutics AB (publ) shares last traded at $19.87, with a volume of 893 shares changing hands.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Calliditas Therapeutics AB (publ) in a research note on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Price Performance

The company has a 50 day moving average of $20.80 and a 200-day moving average of $20.65. The firm has a market capitalization of $578.22 million, a P/E ratio of -12.13 and a beta of 1.51. The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 2.89.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) last released its quarterly earnings results on Wednesday, February 21st. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.02. The business had revenue of $42.45 million during the quarter, compared to the consensus estimate of $36.24 million. Calliditas Therapeutics AB (publ) had a negative return on equity of 104.47% and a negative net margin of 38.72%. During the same period in the previous year, the company posted ($0.01) EPS. On average, sell-side analysts predict that Calliditas Therapeutics AB will post 0.29 EPS for the current year.

Institutional Trading of Calliditas Therapeutics AB (publ)

An institutional investor recently bought a new position in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. bought a new position in Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 980 shares of the company's stock, valued at approximately $25,000. 2.83% of the stock is currently owned by hedge funds and other institutional investors.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.